TRT denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for trt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Testosterone Replacement Therapy as Not FDA-Approved — and How to Appeal

Testosterone replacement therapy (TRT) includes multiple FDA-approved products. A "not FDA-approved" denial from UnitedHealthcare in this context most often arises in one of three scenarios: (1) the specific compound or formulation prescribed — for example, a compounded testosterone product from a compounding pharmacy — lacks individual FDA approval; (2) TRT is being prescribed for a use or patient population outside the labeled FDA indication; or (3) there is a coding or formulary mismatch in how the claim was submitted.

### Why This Denial Is Appealable

If the prescribed product is an FDA-approved testosterone product used for an approved indication, the denial is factually incorrect and should be challenged immediately with the FDA prescribing label as your primary exhibit. If the product is a compounded formulation, the appeal is more complex: compounded drugs are not individually FDA-approved, but they may be medically necessary when commercial alternatives are not clinically appropriate. If the claim is for an off-label use, you may present published clinical guideline organization support and your prescriber's clinical rationale.

### Federal Appeal Framework

• Internal appeal: File a formal written internal appeal. UHC must respond within 30 days (standard) or 72 hours (expedited/urgent).
• External review (ACA §2719): After exhausting the internal appeal, independent external review by an accredited IRO is available. External reviewers evaluate whether treatment meets clinical evidence standards — not just whether the insurer's policy covers it.
• ERISA §503: Employer-plan members are entitled to full-and-fair review including the clinical references and criteria underlying the denial.
• Timeline: File external review within approximately four months of the final internal denial. Expedited review is available when standard timelines threaten health.

### Concrete Appeal Steps

1. Confirm whether the prescribed product is an FDA-approved commercial product or a compounded formulation. 2. If FDA-approved: print the current prescribing label from DailyMed and attach it to the appeal as primary evidence. Request that UHC identify the specific basis for the "not approved" classification. 3. If compounded: your prescriber must document the medical necessity of compounding versus use of an FDA-approved commercial product — specifically why each available commercial alternative is clinically unsuitable. 4. If off-label: your prescriber should document the clinical rationale and reference the applicable guideline organization. 5. Submit the internal appeal; escalate to external review if denied.

### Documentation to Gather

• FDA prescribing label: Downloaded directly from DailyMed for the exact product prescribed — this is your primary document.
• Diagnosis confirmation: Lab work and chart notes establishing hypogonadism and the clinical indication for TRT.
• Prescriber medical-necessity letter: Addressing directly the "not FDA-approved" basis — either refuting it with the label or explaining medical necessity for a compounded alternative.
• Prior treatment history: Any prior TRT products or alternatives tried, with outcomes, to support why this specific product is necessary.
• Clinical severity: Chart notes describing the functional and clinical impact of undertreated hypogonadism.

### Criteria-Mapping Structure

Obtain UHC's published coverage policy for TRT and map each criterion to documentation:

| UHC Policy Requirement | Supporting Evidence | |---|---| | [Copy each criterion verbatim] | [FDA label, chart note, prescriber letter, lab result] |

If UHC's denial letter cites a specific policy or guideline as the basis for the "not approved" classification, your prescriber's letter should address that reference directly.